Citations

Showing 10 of 108162 citations.

Prenatal Maternal Lipopolysaccharide and Mild Newborn Hyperoxia Increase Intrapulmonary Airway but Not Vessel Reactivity in a Mouse Model
Kuper-Sassé, Margaret, MacFarlane, Peter M. , Mayer, Catherine, Martin, Richard J. , Prakash, Y. S. , Raffay, Thomas M. , Prakash, Y S , Pabelick, Christina M.

Mayo Clinic

Children | March 5, 2021 | Volume: 8 | Issue: 3 | Pages: 195

10.3390/children8030195 | PMID 33807828 Get It

Maternal infection is a risk for preterm delivery. Preterm newborns often require supplemental oxygen to treat neonatal respiratory distress. Newborn hyperoxia exposure is associated with airway and vascular hyperreactivity, while the complications of maternal infection are variable. In a mouse model of prenatal maternal intraperitoneal lipopolysaccharide (LPS, embryonic day 18) with subsequent newborn hyperoxia (40% oxygen × 7 days) precision-cut living lung slices were used to measure intrapulmonary airway and vascular reactivity at 21 days of age. Hyperoxia increased airway reactivity to methacholine compared to room air controls. Prenatal maternal LPS did not alter airway reactivity in room air. Combined maternal LPS and hyperoxia exposures increased airway reactivity vs. controls, although maximal responses were diminished compared to hyperoxia alone. Vessel reactivity to serotonin did not significantly differ in hyperoxia or room air; however, prenatal maternal LPS appeared to attenuate vessel reactivity in room air. Following room air recovery, LPS with hyperoxia lungs displayed upregulated inflammatory and fibrosis genes compared to room air saline controls (TNFαR1, iNOS, and TGFβ). In this model, mild newborn hyperoxia increases airway but not vessel reactivity. Prenatal maternal LPS did not further increase hyperoxic airway reactivity. However, inflammatory genes remain upregulated weeks after recovery from maternal LPS and newborn hyperoxia exposures.
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome
LaRovere, Kerri L. , Riggs, Becky J. , Young, Cameron C. , Newhams, Margaret M. , Maamari, Mia , Walker, Tracie C. , Singh, Aalok R. , Dapul, Heda , Hobbs, Charlotte V. , McLaughlin, Gwenn E., Maddux, Aline B. , Clouser, Katharine N. , Rowan, Courtney M. , McGuire, John K. , Gertz, Shira J. , Muñoz, Álvaro Coronado , Irby, Katherine , Levy, Emily R. , Staat, Mary Allen , Feldstein, Leora R. , Halasa, Natasha , Hall, Mark W. , Kong, Michele , Carroll, Christopher L. , Schuster, Jennifer E. , Doymaz, Sule , Loftis, Laura L. , Tarquinio, Keiko M. , Babbitt, Christopher , Nofziger, Ryan A. , Kleinman, Lawrence C. , Keenaghan, Michael , Spinella, Philip C. , Hume, Janet R. , Wellnitz, Kari , Mack, Elizabeth H. , Flori, Heidi R. , Patel, Manish M. , Randolph, Adrienne G. , Investigators, Overcoming COVID-19, Name, First Name and Middle Initial Last, Gaspers, Mary Glas , Typpo, Katri , Sanders, Ronald C., Schwarz, Adam J. , Harvey, Helen , Mourani, Peter M. , Coates, Bria M. , Bhoojhawon, Guru , Havlin, Kevin , Sullivan, Janice E, Bradford, Tamara T. , Lipton, Susan V., Chen, Sabrina , Kücükak, Suden, Carroll, Ryan W. , Fernandes, Neil D. , Yager, Phoebe H. , Marohn, Kimberly L, Heidemann, Sabrina M. , Cullimore, Melissa L. , Horwitz, Steven M. , Walsh, Rowan, Soma, Vijaya L, Gillen, Jennifer , Zackai, Sheemon, Ackerman, Kate G. , Cholette, Jill M., Hymes, Saul , Overby, Philip , Schwartz, Stephanie P. , Lansell, Amanda , Koncicki, Monica L. , Carcillo, Joseph A. , Bowens, Cindy , Crandall, Hillary , Smith, Lincoln , Cengiz, Pelin , Levy, Emily R , Young, Cameron C , Randolph, Adrienne G , Spinella, Philip C , Kong, Michele , Hume, Janet R , Hobbs, Charlotte V , Maddux, Aline B , Staat, Mary A , Gertz, Shira J , Schwartz, Stephanie P , Hymes, Saul R , Poussaint, Tina Young , Son, Mary Beth F. , Fitzgerald, Julie C. , Shein, Steven L. , Thomas, Neal J. , Tenforde, Mark W. , Giuliano, John S. , Cvijanovich, Natalie Z , Michelson, Kelly Nicole , Investigators, Overcoming COVID-19, Zinter, Matt S. , Montgomery, Vicki , Sullivan, Janice E, Bembea, Melania M. , Graciano, Ana Lía , Newburger, Jane W. , Marohn, Kimberly L, McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , Harwayne‐Gidansky, Ilana , Fink, Ericka L. , Kimura, Dai

Mayo Clinic

JAMA Neurology | March 5, 2021 | Volume: 78 | Issue: 5 | Pages: 536

10.1001/jamaneurol.2021.0504 | PMID 33666649 Get It

Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology
Wiebe, Samuel , Jeppesen, Jesper , Tatum, William O. , Brázdil, Milan , Wang, Yuping , Herman, Susan T. , Ryvlin, Philippe , Beniczky, Sándor , Wiebe, Samuel , Jeppesen, Jesper , Tatum, William O , Brazdil, Milan , Ryvlin, Philippe

Mayo Clinic

Epilepsia | March 5, 2021 | Volume: 62 | Issue: 3 | Pages: 632-646

10.1111/epi.16818 | PMID 33666944 Get It

Abstract The objective of this clinical practice guideline (CPG) is to provide recommendations for healthcare personnel working with patients with epilepsy on the use of wearable devices for automated seizure detection in patients with epilepsy, in outpatient, ambulatory settings. The Working Group of the International League Against Epilepsy (ILAE) and the International Federation of Clinical Neurophysiology (IFCN) developed the CPG according to the methodology proposed by the ILAE Epilepsy Guidelines Working Group. We reviewed the published evidence using The Preferred Reporting Items for Systematic Review and Meta‐Analysis (PRISMA) statement and evaluated the evidence and formulated the recommendations following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. We found high level of evidence for the accuracy of automated detection of generalized tonic‐clonic seizures (GTCS) and focal‐to‐bilateral tonic‐clonic seizures (FBTCS) and recommend the use of wearable automated seizure detection devices for selected patients when accurate detection of GTCS and FBTCS is recommended as a clinical adjunct. We also found a moderate level of evidence for seizure types without GTCS or FBTCS. However, it was uncertain whether the detected alarms resulted in meaningful clinical outcomes for the patients. We recommend using clinically validated devices for automated detection of GTCS and FBTCS, especially in unsupervised patients, where alarms can result in rapid intervention (weak/conditional recommendation). At present, we do not recommend clinical use of the currently available devices for other seizure types (weak/conditional recommendation). Further research and development are needed to improve the performance of automated seizure detection and to document their accuracy and clinical utility.
Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: A systematic analysis of the Global Burden of Disease Study 1990–2017
Azadnajafabad, Sina , Moghaddam, Sahar Saeedi , Mohammadi, Esmaeil , Rezaei, Negar , Ghasemi, Erfan , Fattahi, Nima , Aminorroaya, Arya , Azadnajafabad, Reza , Aryannejad, Armin , Rezaei, Nazila , Naderimagham, Shohreh , Mokdad, Ali H. , Gharib, Hossein, Farzadfar, Farshad , Larijani, Bagher , Saeedi Moghaddam, Sahar , Farzadfar, Farshad , Rezaei, Negar , Larijani, Bagher , Rezaei, Nazila , Haghpanah, Vahid

Mayo Clinic

Cancer Medicine | March 5, 2021 | Volume: 10 | Issue: 7 | Pages: 2496-2508

10.1002/cam4.3823 | PMID 33665966 Get It

AbstractBackgroundThyroid cancer (TC) is the most prevalent malignancy of the endocrine system. Over the past decades, TC incidence rates have been increasing. TC quality of care (QOC) has yet to be well understood. We aimed to assess the quality of TC care and its disparities.MethodsWe retrieved primary epidemiologic indices from the Global Burden of Disease (GBD) 1990–2017 database. We calculated four secondary indices of mortality to incidence ratio, disability‐adjusted life years (DALYs) to prevalence ratio, prevalence to incidence ratio, and years of life lost (YLLs) to years lived with disability (YLD) ratio and summarized them by the principal component analysis (PCA) to produce one unique index presented as the quality of care index (QCI) ranged between 0 and 100, to compare different scales. The gender disparity ratio (GDR), defined as the QCI for females divided by QCI for males, was applied to show gender inequity.ResultsIn 2017, there were 255,489 new TC incident cases (95% uncertainty interval [UI]: 245,709–272,470) globally, which resulted in 41,235 deaths (39,911–44,139). The estimated global QCI was 84.39. The highest QCI was observed in the European region (93.84), with Italy having the highest score (99.77). Conversely, the lowest QCI was seen in the African region (55.09), where the Central African Republic scored the lowest (13.64). The highest and lowest socio‐demographic index (SDI) regions scored 97.27 and 53.85, respectively. Globally, gender disparity was higher after the age of 40 years and in favor of better care in women.ConclusionTC QOC is better among those countries of higher socioeconomic status, possibly due to better healthcare access and early detection in these regions. Overall, the quality of TC care was higher in women and younger adults. Countries could adopt the introduced index of QOC to investigate the quality of provided care for different diseases and conditions.
Six years of gender equity in emergency medicine chief resident selection
Farrell, Kyle , Walker, Laura , Battaglioli, Nicole , Heaton, Heather A. , Lohse, Christine M. , Sadosty, Annie T., Farrell, Kyle J , Walker, Laura E , Lohse, Christine

Mayo Clinic

AEM Education and Training | March 5, 2021 | Volume: 5 | Issue: 2 | Pages: No page available

10.1002/aet2.10595 | PMID 33869983 Get It

Healthcare disparities among anticoagulation therapies for severe COVID‐19 patients in the multi‐site VIRUS registry
Kirkup, Christian , Puranik, Arjun, Conrad, Ian, Gomaa, Dina , Mosier, Jarrod , Заболотских, И. Б. , Daugherty, Steven K., Bernstein, Michael, Zaren, Howard A. , Bansal, Vikas , Pickering, Brian , Badley, Andrew D. , Camazine, Maraya , Koritala, Thoyaja , O'Horo, John C, Bansal, Vikas , Soundararajan, Venky , Badley, Andrew D , Mosier, Jarrod M , Pawlowski, Colin , O’Horo, John C. , Banner‐Goodspeed, Valerie , Kashyap, Rahul , Venkatakrishnan, A J , Soundararajan, Venky

Mayo Clinic

Journal of Medical Virology | March 5, 2021 | Volume: 93 | Issue: 7 | Pages: 4303-4318

10.1002/jmv.26918 | PMID 33666246 Get It

Abstract Here we analyze hospitalized andintensive care unit coronavirus disease 2019 (COVID‐19) patient outcomes from the international VIRUS registry ( https://clinicaltrials.gov/ct2/show/NCT04323787 ). We find that COVID‐19 patients administered unfractionated heparin but not enoxaparin have a higher mortality‐rate (390 of 1012 = 39%) compared to patients administered enoxaparin but not unfractionated heparin (270 of 1939 = 14%), presenting a risk ratio of 2.79 (95% confidence interval [CI]: [2.42, 3.16]; p = 4.45e−52). This difference persists even after balancing on a number of covariates including demographics, comorbidities, admission diagnoses, and method of oxygenation, with an increased mortality rate on discharge from the hospital of 37% (268 of 733) for unfractionated heparin versus 22% (154 of 711) for enoxaparin, presenting a risk ratio of 1.69 (95% CI: [1.42, 2.00]; p = 1.5e−8). In these balanced cohorts, a number of complications occurred at an elevated rate for patients administered unfractionated heparin compared to patients administered enoxaparin, including acute kidney injury, acute cardiac injury, septic shock, and anemia. Furthermore, a higher percentage of Black/African American COVID patients (414 of 1294 [32%]) were noted to receive unfractionated heparin compared to White/Caucasian COVID patients (671 of 2644 [25%]), risk ratio 1.26 (95% CI: [1.14, 1.40]; p = 7.5e−5). After balancing upon available clinical covariates, this difference in anticoagulant use remained statistically significant (311 of 1047 [30%] for Black/African American vs. 263 of 1047 [25%] for White/Caucasian, p = .02, risk ratio 1.18; 95% CI: [1.03, 1.36]). While retrospective studies cannot suggest any causality, these findings motivate the need for follow‐up prospective research into the observed racial disparity in anticoagulant use and outcomes for severe COVID‐19 patients.
Macrophage Heterogeneity in NASH: More Than Just Nomenclature
Parthasarathy, Gopanandan , Malhi, Harmeet , Malhi, Harmeet

Mayo Clinic

Hepatology | March 5, 2021 | Volume: 74 | Issue: 1 | Pages: 515-518

10.1002/hep.31790 | PMID 33666272 Get It

WITHDRAWN–How to Help Your Patients Enroll in the New-Onset Refractory Status Epilepticus (NORSE) and Febrile Infection-Related Epilepsy Syndrome (FIRES) Family Registry, and Other Rare Epilepsy Registries
Kellogg, Marissa , Wong, Nora , Moeller, Raquel Farias, Gaspard, Nicolas , Hocker, Sara E. , Kazazian, Karnig , Gaspard, Nicolas , Hocker, Sara, Kazazian, Karnig , Wong, Nora, Eschbach, Krista , Hirsch, Lawrence J. , Gofton, Teneille

Mayo Clinic

Epilepsy Currents | March 5, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/1535759721998329 | PMID 33663265 Get It

Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases
Chang, Alice Y. , Mirfakhraee, Sasan , King, Elizabeth E., Mercado, Jennifer U., Donegan, Diane , Yuen, Kevin C.J.

Mayo Clinic

Clinical Medicine Insights: Endocrinology and Diabetes | March 5, 2021 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/1179551421994102 | PMID 33746521 Get It

Establishing a definitive diagnosis of Cushing disease (CD), given its clinical and biochemical heterogeneity, initiating effective treatment to control the effects of hypercortisolism, and managing recurrence are challenging disease aspects to address. Mifepristone is a competitive glucocorticoid receptor antagonist that is approved in the US by the Food and Drug Administration to control hyperglycemia secondary to endogenous hypercortisolism (Cushing syndrome) in patients who have glucose intolerance or type 2 diabetes mellitus and have failed surgery or are not candidates for surgery. Herein, we describe 6 patients with CD who received mifepristone as adjunct/bridge therapy in the following clinical settings: to assess clinical benefits of treatment for suspected recurrent disease, to control hypercortisolism preoperatively for severe disease, to control hypercortisolism during the COVID-19 pandemic, and to provide adjunctive treatment to radiation therapy. The patients were treated at multiple medical practice settings. Mifepristone treatment in each of the described cases was associated with clinical improvements, including improvements in overall glycemia, hypertension, and weight loss. In addition, in one case where biochemical and radiological evidence of disease recurrence was uncertain, clinical improvement with mifepristone pointed toward likely disease recurrence. Adverse events associated with mifepristone reported in the 6 cases were consistent with those previously reported in the pivotal trial and included cortisol withdrawal symptoms, antiprogesterone effects (vaginal bleeding), hypothyroidism (treated with levothyroxine), and hypokalemia (treated with spironolactone). These cases show how mifepristone can potentially be utilized as a therapeutic trial in equivocal cases of CD recurrence; as a presurgical treatment strategy, particularly during the COVID-19 pandemic; and as bridge therapy, while awaiting the effects of radiation.
Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?
Evgin, Laura , Vile, Richard G.

Mayo Clinic

Cancers | March 5, 2021 | Volume: 13 | Issue: 5 | Pages: 1106

10.3390/cancers13051106 | PMID 33807553 Get It

Oncolytic viruses (OVs) and adoptive T cell therapy (ACT) each possess direct tumour cytolytic capabilities, and their combination potentially seems like a match made in heaven to complement the strengths and weakness of each modality. While providing strong innate immune stimulation that can mobilize adaptive responses, the magnitude of anti-tumour T cell priming induced by OVs is often modest. Chimeric antigen receptor (CAR) modified T cells bypass conventional T cell education through introduction of a synthetic receptor; however, realization of their full therapeutic properties can be stunted by the heavily immune-suppressive nature of the tumour microenvironment (TME). Oncolytic viruses have thus been seen as a natural ally to overcome immunosuppressive mechanisms in the TME which limit CAR T cell infiltration and functionality. Engineering has further endowed viruses with the ability to express transgenes in situ to relieve T cell tumour-intrinsic resistance mechanisms and decorate the tumour with antigen to overcome antigen heterogeneity or loss. Despite this helpful remodeling of the tumour microenvironment, it has simultaneously become clear that not all virus induced effects are favourable for CAR T, begging the question whether viruses act as valets ushering CAR T into their active site, or vandals which cause chaos leading to both tumour and T cell death. Herein, we summarize recent studies combining these two therapeutic modalities and seek to place them within the broader context of viral T cell immunology which will help to overcome the current limitations of effective CAR T therapy to make the most of combinatorial strategies.